Agree Realty Explores Innovative Lung Cancer Treatment: Sacituzumab Tirumotecan Approved in China
- Sacituzumab tirumotecan is the first ADC approved for advanced EGFR-mutant NSCLC after TKI therapy in China.
- The drug shows significant overall survival benefits compared to standard platinum chemotherapy in resistant lung cancer patients.
- Its approval marks a major advancement in targeted therapies, enhancing treatment options for patients with limited alternatives.
Innovative Breakthrough in Lung Cancer Treatment: Sacituzumab Tirumotecan Approved in China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. achieves a significant milestone with the approval of its groundbreaking antibody-drug conjugate (ADC), sacituzumab tirumotecan (sac-TMT), by the National Medical Products Administration (NMPA) in China. This approval is specifically for adult patients suffering from epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have experienced progression after treatment with EGFR-tyrosine kinase inhibitors (TKIs). The significance of sac-TMT extends beyond its approval; it is the first ADC worldwide to show a notable overall survival (OS) benefit when compared to platinum doublet chemotherapy in this challenging patient demographic.
The importance of sac-TMT's approval cannot be understated, as it is currently the only approved monotherapy targeting advanced EGFR-mutant NSCLC after TKI therapy or a combination of TKI therapy with platinum chemotherapy. This unique position effectively addresses the needs of patients who are resistant to traditional treatments, offering a new hope for those who have limited options following TKI failure. In the pivotal Phase III study, known as OptiTROP-Lung04, sac-TMT was administered at a dosage of 5 mg/kg every two weeks, yielding statistically significant and clinically meaningful enhancements in both progression-free survival (PFS) and overall survival compared to standard platinum-based chemotherapy protocols.
Furthermore, the clinical implications of this approval resonate on a broader scale, marking a pioneering achievement in the realm of ADCs for lung cancer treatment within the Chinese population. The findings from the Phase III trial will be highlighted as a late-breaking abstract at the 2025 European Society for Medical Oncology (ESMO) Congress, reflecting the global interest in the advancements of lung cancer therapies. With sac-TMT's earlier approval in March 2025 for patients who had already failed both EGFR-TKI and platinum chemotherapy, it solidifies the drug's critical role in the evolving landscape of advanced NSCLC treatment.
In related news, the biopharmaceutical landscape continues to evolve, with an increasing focus on personalized medicine and targeted therapies. Companies like Sichuan Kelun-Biotech are at the forefront of this shift, developing innovative treatments that cater to specific patient populations and genetic markers. As research progresses, the need for effective solutions in oncology remains paramount, highlighting the vital role of companies in this sector.
Related Cashu News

Lamar Advertising Co Moves to Value Indices Amid Shift in Investment Strategies
Lamar Advertising Co (Ticker: LAMR) has recently undergone a significant change in its market classification by being added to several Russell value and defensive indices. This inclusion reflects a sh…

Alexandria Real Estate Equities Advances Corporate Responsibility and Strengthens Its Position in Life Sciences
Alexandria Real Estate Equities (ARE) has made significant strides in enhancing its corporate responsibility efforts, as detailed in its recently published 2025 Corporate Responsibility Report. The re…

Healthpeak OP LLC Achieves Key Index Inclusion, Boosting Investor Interest and Trading Activity
Healthpeak OP LLC (Ticker: DOC) leverages significant market developments to reinforce its position in the real estate investment trust sector through strategic index inclusion, which may reshape inve…

Public Storage Boosts Financial Flexibility with New Credit Facility and Commercial Paper Program
Public Storage (Ticker: PSA) enhances its financial flexibility with a new unsecured credit facility and commercial paper program. Strategic Financial Innovations The company announces the closure of…

